ArticleFrontiers in oncology2026
Case Report: Chemotherapy, immunotherapy, and radiotherapy achieve complete response for metastatic ureteral urothelial carcinoma with significant squamous differentiation.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The majority of tumors in the upper urinary tract are classified as urothelial carcinomas, with only 15% exhibiting different levels of squamous differentiation, known as the squamous subtype. These tumors tend to be more aggressive and are associated with a worse prognosis compared to standard urothelial carcinomas. Case presentation: A 60-year-old man was found to have cancer in his left ureter and subsequently underwent a robot-assisted laparoscopic procedure to partially remove the left ureter and perform a ureterovesical anastomosis. The postoperative analysis revealed high-grade urothelial carcinoma with marked squamous differentiation(40% squamous differentiation) and microsatellite stability (MSS). Three months after surgery, the abdominal incision recurred and abdominal mass resection was performed again. One month after abdominal surgery, imaging evaluation showed lymph node metastasis in the left lower wall of the bladder and retroperitoneum.Ultimately, the patient attained complete imaging remission following treatment with the \GC\ chemotherapy regimen, along with \tislelizumab\ immunotherapy and radiotherapy. Conclusion: The \GC\ chemotherapy protocol, along with \tislelizumab\ immunotherapy and radiotherapy, shows remarkable effectiveness in treating metastatic ureteral urothelial carcinoma with significant squamous differentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.